跳到正文
The Decoder· Maximilian Schreiner·· 6 小时前AI 评分66

Isomorphic Labs 六个月内完成第二笔 50 亿美元融资

Isomorphic Labs raises $5 billion in its second mega-round within six months

AI 导读

Alphabet 旗下 AI 药物研发公司 Isomorphic Labs 完成 50 亿美元融资,由 Greenoaks 和 Sequoia Capital 联合领投,Andreessen Horowitz 及 Alphabet 等现有投资方参投;该公司今年 5 月已融资 21 亿美元。

正文 · 原文

Alphabet's AI drug discovery company Isomorphic Labs has raised $5 billion, its second billion-dollar round in six months. Greenoaks and Sequoia Capital co-led the round, joined by new backer Andreessen Horowitz along with Alphabet and all existing investors.

The company had already raised $2.1 billion back in May 2026. The money will go toward advancing its in-house platform IsoDDE (Isomorphic Drug Design Engine) and pushing its drug pipeline toward clinical trials. IsoDDE goes beyond AlphaFold 3, according to the company founded in 2021, and aims to better predict drug binding and docking sites. Isomorphic Labs works with Novartis, Eli Lilly, and Johnson & Johnson but has no approved drug to show for it yet.

The company is led by Demis Hassabis, who stepped down from day-to-day leadership of Google Deepmind in August 2026 and now serves as Alphabet's Chief Scientist. Hassabis won the 2024 Nobel Prize in Chemistry alongside John Jumper for their work on AlphaFold.

Deepmind's original AlphaFold team was disbanded in July 2026. Many researchers moved to Isomorphic Labs or were reassigned to other projects. Nearly a quarter left Deepmind entirely. Deepmind still shipped AlphaGenome 2 in early November 2026, which predicts how DNA variants affect gene activity in specific cell types.

AI News Without the Hype – Curated by Humans

Subscribe to THE DECODER for ad-free reading, a weekly AI newsletter, our exclusive "AI Radar" frontier report six times a year, full archive access, and access to our comment section.

来源:The Decoder · the-decoder.com